https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32659 Wed 19 Jan 2022 15:19:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51016 Wed 16 Aug 2023 09:14:24 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51735 Wed 13 Mar 2024 08:10:40 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48754 Wed 05 Apr 2023 13:48:37 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44739 Wed 03 May 2023 13:55:37 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52002 Tue 26 Sep 2023 11:30:29 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54356 Tue 20 Feb 2024 16:25:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50321 Tue 18 Jul 2023 15:05:24 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51747 Thu 21 Mar 2024 13:55:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49308 Thu 11 May 2023 14:40:16 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45398 Thu 10 Nov 2022 08:38:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46839 Thu 01 Dec 2022 15:29:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46836 Thu 01 Dec 2022 15:01:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49716 Mon 29 May 2023 14:59:51 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47457 Mon 23 Jan 2023 09:48:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53956 Mon 22 Jan 2024 17:02:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42628 Mon 19 Jun 2023 14:35:48 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52345 The purpose of this study was to evaluate the effect of custom-made orthotics on pain, health-related quality of life (HRQoL), function and fatigue in children and adolescents with generalised joint hypermobility (GJH) and lower limb pain. Fifty-three children aged 5–18 years were fitted with custom-made polypropylene orthotics. Visual analogue scale (VAS) assessed lower limb pain severity, Paediatric Quality of Life Inventory assessed HRQoL and fatigue and six-minute walk test (6 MWT) measured functional endurance at baseline, at 1 month and 3 months post-intervention. A mixed model including a random intercept for participant and a fixed effect for time was used to assess differences in outcomes over time. Fifty-two children completed the study (mean age 10.6-years). Children reported significantly reduced pain (mean VAS reduction −27/100, 95%CI: −33, −21), improved HRQoL (mean total improvement 11/100, 95%CI: 7, −15), functional capacity (mean 6MWT improvement 27 m, 95%CI: 18, −36) and fatigue (mean total improvement 13/100, 95%CI: 9, −17) after 1 month of wearing the custom-made orthotics. From 1 month to 3 months there was further statistically but not clinically significant reduction in pain while benefit on other outcomes was maintained. In this study, children with GJH reported reduced lower limb pain, improved HRQoL, functional endurance and fatigue after a month post-fitting of custom-made orthotics which was maintained over a 3 month period. Orthotics were well-tolerated with no serious adverse events reported.]]> Mon 09 Oct 2023 14:57:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39254 P = 0.1407). Fewer patients breached the National Emergency Access Target (NEAT) when the KALM pathway was used (56%, n = 28 vs 64%, n = 108, P = 0.252). There were no significant differences in the carer survey between the two care pathways. Conclusion: This study provides valuable information about the benefits of the KALM pathway in managing child and adolescent MH presentations to ED. This new pathway reduces the LOS in ED and improves carer experience compared to the usual care pathway.]]> Fri 27 May 2022 15:56:29 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51892 Fri 22 Sep 2023 09:23:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54956 Fri 22 Mar 2024 15:28:41 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39652 s) was 2.2 (±1.0 SD) days. The primary outcome, 30-day mortality, occurred in 16 (14%) patients with secondary outcomes of SAEs in 25 (22%) patients and transfusion in 30 (27%) patients. T_s (days) did not significantly affect 30-day mortality (odds ratio (OR): 1.37, 95% confidence interval (CI): 0.80–2.33; p = 0.248), SAE (hazard ratio (HR): 1.03, 95% CI: 0.70–1.52; p = 0.885), transfusion (OR: 0.72 95% CI: 0.45 to 1.16; p = 0.177) or POD 1 Hb (OR: 1.99, 95% CI: −0.59 to 4.57; p = 0.129). Timing of surgery does not influence common surgical outcomes such as 30-day mortality, SAE, transfusion, and POD1 Hb in patients taking DOACs on admission.]]> Fri 17 Jun 2022 13:19:06 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49390 Fri 12 May 2023 14:35:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49826 Fri 02 Jun 2023 16:17:47 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51369 Fri 01 Sep 2023 13:44:39 AEST ]]>